The purchase of chloroquine by the administration of President Jair Bolsonaro (PL) at the height of the Kovid-19 epidemic and the vaccine contracts signed by the government that expire at the end of December will be subject to scrutiny by the new Brazilian government. from 2023.

Sources from the healthcare transition team confirmed to UOL that when he took power, the new administration had the intention to seek clarification on the motivations for these acquisitions, which were against the guidelines when it comes to chloroquine. scientists and WHO itself.

HE UOL He had already laid out what a declassification process should look like at Itamaraty, which will include examining issues related to the pandemic.

But according to members of the transition team, the job will go far beyond opening confidential documents or secret diplomatic correspondence. The purpose of the analysis in the Ministry of Health is to reveal what the chain of command is in decision-making, where the guidelines come from, and how the consultation process with the technical and scientific team is.

For resources in the transition team, the Covid-19 CPI has done important work in trying to understand how vaccine and chloroquine purchases are made and how the use of the public machine is set up to make such actions happen.

However, the assessment is that the process does not end with the CPI report, and the conclusions now need to be deepened with new research.

In mid-2020, WHO suspended research into the supposed effectiveness of chloroquine after an effort involving dozens of hospitals around the world.

However, weeks later, the State Department announced that the US government had delivered 2 million doses of hydroxychloroquine to Brazil as a “token of solidarity” between the two countries in the fight against coronavirus.
????????
“HCQ [hidroxicloroquina] It will be used prophylactically to help protect nurses, doctors and healthcare workers in Brazil against the virus. It will also be used to treat infected Brazilians,” the note wrote at the time.

Arthur Weintraub suggested that a Nuremberg tribunal be set up against people who refused to prescribe the drug.

Shortly after exporting 2 million doses to Brazil, US officials announced their decision to revoke the “emergency use authorization that allows chloroquine phosphate and hydroxychloroquine sulfate to be used outside of clinical trials to treat certain patients hospitalized with COVID-19.”

Within Itamaraty, the sale to Brazil and the suspension in the US were ridiculed by diplomats and seen as a dubious gesture by actors within the government who insisted on the relationship between Donald Trump and allies of Jair Bolsonaro.

While Brazil purchased the American drug, the U.S. Food and Drug Administration (FDA) determined that in the case of chloroquine, “the legal criteria for authorizing emergency use are no longer met.” The FDA is an agency of the United States Department of Health and Human Services.

“Based on its ongoing review and emerging scientific data, the FDA has determined that chloroquine and hydroxychloroquine are unlikely to be effective in the treatment of COVID-19 for uses permitted in the United States,” US officials said.

“Furthermore, in light of ongoing serious cardiac events and other potentially serious side effects, the known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks of their authorized use,” they said.

In the case of America, he insisted that government decisions were based on science. “Throughout this public health emergency, we have been clear that science will guide our actions and that our decisions may change as we learn more about the SARS-CoV-2 virus, review the latest data, and consider the balance of risks and benefits. FDA Assistant Commissioner for Medical and Scientific Affairs. “The number of treatments for COVID-19,” said Anand Shah.